Lepu Biopharma Co. Ltd., a joint stock company incorporated in the People's Republic of China, has announced that it has received listing approval from the Stock Exchange of Hong Kong for the conversion and listing of 54,268,364 H shares. This approval marks a significant step in the company's efforts to expand its shareholding structure, allowing for the conversion of unlisted shares into listed ones. The announcement was made official on June 19, 2025, following the issuance of the Filing Notice by the China Securities Regulatory Commission (CSRC). The company has advised shareholders and potential investors to exercise caution when dealing in its shares. No other organizations were mentioned as recipients of this grant or approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.